Giampaolo Bianchini

📢1/10 Out on @Nature our work ‘Spatial predictors of immunotherapy response in triple-negative breast cancer’ rdcu.be/dluy0 lead by @HRazaAliLab and myself 👉To work, immunotherapy requires certain immune cell types, in proper functional state and spatial context 🧵👇

Great point! Indeed, we analyzed the recurrence patterns in pts with RD treated with chemo alone, and there didn’t appear to be any significant differences compared to those treated with chemo/immuno (see Suppl. Fig. 1). Thank you so much! 😃

Online Now: A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture dlvr.it/TM3kdh

🆕review in press: Clinical challenges and proposed solutions for patients with invasive lobular breast cancer @ChristineDesme2 doi.org/10.1016/j.anno…

There is an urgent need for a new age algorithm that takes huge existing data sets and calculates 3,5,10 year benefits to Chemotherapy, endocrine therapy, CDK4/6i and bisphosphonates in adjuvant HR+,HER2- Breast Cancer. Predict NHS but new and better. I’m sure AI could help.

Addition of pembrolizumab to enzalutamide and androgen deprivation therapy is not effective in metastatic hormone-sensitive prostate cancer fondazionebonadonna.org/en/pembrolizum… #FondazioneBonadonna #Oncology #CancerResearch @BianchiniGP @CarmenCriscit @mauricallari

🚨Just out in @CCR_AACR our analysis on the recurrence timing after neoadjuvant chemo-immunotherapy in early-stage TNBC We analyzed 5 major trials 👉 Early relapse: up to 83% of all recurrences🤯 1/ 🧵 Why this matters 👇 🔗 Full article: doi.org/10.1158/1078-0…

1/ No, you do not always need single-cell RNA-seq. Here's why bulk RNA-seq might still be the smarter move for your experiment.

📢 New in @OncJournal 👉 DOI: doi.org/10.1093/oncolo… 📊In the GIM12-TYPHER phase II trial, trastuzumab (T) + lapatinib showed comparable efficacy & better QoL vs. chemo + T in pretreated HER2+ MBC 🏆Another successful effort by the 🇮🇹 GIM group!

Expected pathological complete response rates in early stage II/III HER2+ breast cancer. #bcsm @DFCI_BreastOnc

This is interesting. By binding to NK1R, the P protein can affect several aspects of cancer hallmarks. This intriguing article suggests an anticaner role for NK1R inhibitors commonly used to treat severe nausea an vomiting due to chemotherapy. pubmed.ncbi.nlm.nih.gov/40658620/

The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets dlvr.it/TLyB5j

And back to back publication of IBI343, another CLDN18.2 TOPO1i ADC. In this case, exatecan payload using Synaffix technology. Better response rates in moderate to high CLDN18.2 expression vs moderate. And overall better safety at 6.0 mg/kg Q3W (dose chosen for ongoing phase 3)

1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in @Cancer_Cell cell.com/cancer-cell/fu…

Inavosilib plus palbociclib-fulvestrant led to a significant survival benefit versus placebo plus palbociclib-fulvestrant in PIK3CA-mutated advanced breast cancer fondazionebonadonna.org/en/inavosilib-… #FondazioneBonadonna #Oncology #CancerResearch @BianchiniGP @CarmenCriscit @mauricallari

Forza @delmastro_lucia INSIEME per @AIOMtweet

Forza @delmastro_lucia…tutti #INSIEME…per @AIOMtweet !!!! @OncoAlert @UniGenova @Lucarecco @Poggio_Fra @M_Tagliamento @DSoldatoMD @CarloGenova5 @MRazeti @ChiaraMolinelli @boutrosand

N1 axillary disease post neoadjuvant chemo in Early Stage Breast Cancer? If clinically N0, SLNB with >= 3 nodes or TAD is fine. Residual ITCs: ALND can be avoided. Residual micromets: ALND could be avoided, still standard for TNBC. Residual macromets: ALND still standard.

Phase 1b of BL-B01D1 (EGFRxHER3 TOPO1i BsADC) in esophageal squamous cell carcinoma published on @NatureMedicine 2.5 mg/kg D1D8 Q3W, ORR=40% (21/53) 2.0 mg/kg D1D8 Q3W, ORR=15% (3/20) No significant correlation between response and expression of EGFR, HER3, or both (small #).

Many cancer patients are prescribed gabapentin for neuropathy symptoms. This finding of increased risk of dementia with gabapentin should be an important factor in use of this agent.

Exercise is medicine. Physically active breast cancer survivors had 31% (95% CI: 25–37%) reduction in risk of breast cancer mortality relative to physically inactive pts. pmc.ncbi.nlm.nih.gov/articles/PMC12…